Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 14/20 | 0.56 |
| ▸ | NR1H3 | Q13133 | 14/20 | 0.56 |
| ▸ | MLYCD | O95822 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16125053 | 0.89 | NR1H2 (0.50) | NR1H2NR1H3MLYCDSMN1; SMN2 | |
| SCHEMBL131990 | 0.87 | NR1H2 (0.68) | NR1H2NR1H3MLYCDSMN1; SMN2 | |
| Water SCHEMBL1684070 | 0.84 | NR1H2 (0.65) | NR1H2NR1H3MLYCDSMN1; SMN2 | |
| SCHEMBL24901413 | 0.79 | NR1H2 (0.61) | NR1H2NR1H3MLYCDSMN1; SMN2 | |
| SCHEMBL9621271 | 0.79 | NR1H2 (0.60) | NR1H2NR1H3MLYCDSMN1; SMN2 | |
| SCHEMBL12334379 | 0.79 | RORC (0.77) | SMN1; SMN2 | |
| SCHEMBL1516045 | 0.77 | ESR1 (0.61) | NR1H2NR1H3MLYCDSMN1; SMN2 | |
| SCHEMBL6808538 | 0.77 | ESR1 (0.61) | NR1H2NR1H3MLYCDSMN1; SMN2 | |
| SCHEMBL8021367 | 0.77 | NR1H2 (0.58) | NR1H2NR1H3MLYCDSMN1; SMN2 | |
| SCHEMBL18846 | 0.76 | HSD11B1 (0.54) | NR1H3CA1CA2CA5ACA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240076297-A1 | ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY | MERCK SHARP & DOHME LLC (US) | 2024-03-07 | — | — | US | disclosed |
| US-20230322785-A1 | ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY | MERCK SHARP & DOHME LLC (US) | 2023-10-12 | — | — | US | disclosed |
| US-11785845-B2 | Composition | FUJIFILM CORPORATION (JP) | 2023-10-10 | — | — | US | disclosed |
| EP-4185297-A1 | ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY | Merck Sharp & Dohme LLC (US) | 2023-05-31 | — | — | EP | disclosed |
| CN-113666853-B | Biaryl compounds useful as ROR gamma modulators | 上海辉启生物医药科技有限公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-113666853-A | Biaryl compounds useful as ROR gamma modulators | 上海辉启生物医药科技有限公司 | 2021-11-19 | — | — | CN | disclosed |
| CN-113666863-A | Biaryl compounds useful as ROR gamma modulators | 上海辉启生物医药科技有限公司 | 2021-11-19 | — | — | CN | disclosed |
| WO-2021228216-A1 | BIARYL COMPOUND CAPABLE OF SERVING AS RORγ MODULATOR | 上海辉启生物医药科技有限公司 | 2021-11-18 | — | — | WO | disclosed |
| WO-2021228215-A1 | BIARYL COMPOUND CAPABLE OF SERVING AS RORγ REGULATOR | 上海辉启生物医药科技有限公司 | 2021-11-18 | — | — | WO | disclosed |
| WO-2020045214-A1 | RESIN COMPOSITION AND CURED FILM OBTAINED THEREFROM | 東レ株式会社 | 2020-03-05 | — | — | WO | disclosed |
| US-5710170-A | Tri-aryl ethane derivatives as PDE IV inhibitors | MERCK FROSST CANADA, INC. (CA) | 1998-01-20 | — | — | US | disclosed |
| WO-1997022586-A1 | TRI-ARYL ETHANE DERIVATIVES AS PDE IV INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1997-06-26 | — | — | WO | disclosed |
| US-5319131-A | Reacting dimethyl 2-fluoromalonate with formaldehyde to form hydroxymethylated dimethyl 2-flurormalonate, hydrolysis, decarboxylation, dehydration then esterification with a hexafluoroalkylol | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-06-07 | — | — | US | disclosed |
| US-5198925-A | α-fluoroacrylic acid esters and polymers thereof | HOECHST AKTIENGESELLSCHAFT | 1993-03-30 | — | — | US | disclosed |
| CN-1010098-B | Process for preparing alpha-fluoroacrylate polymers | HOECHST AG (DE) | 1990-10-24 | — | — | CN | disclosed |
| EP-0203462-B1 | ALPHA-FLUOROACRYLIC-ACID ESTERS AND THEIR POLYMERS | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-08-01 | — | — | EP | disclosed |
| CN-1006380-B | Preparation method of alpha-fluoroacrylate and polymer thereof | HOECHST AG (DE) | 1990-01-10 | — | — | CN | disclosed |
| CN-1036209-A | Process for preparing alpha-fluoroacrylate polymers | HOECHST AG (DE) | 1989-10-11 | — | — | CN | disclosed |
| CN-86103531-A | Alpha-fluoroacrylates and polymers thereof | — | 1987-01-28 | — | — | CN | disclosed |
| EP-0203462-A2 | Alpha-fluoroacrylic-acid esters and their polymers | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-12-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240076297-A1 | ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY | ADORA2A, ADORA2B, ADORA1 | NR1H2 1871/4885NR1H3 2307/4885MLYCD 4794/4885 |
| US-11785845-B2 | Composition | ADH1A, ADH1C, SLC19A2 | NR1H2 794/4885NR1H3 515/4885MLYCD 3157/4885 |
| US-20230322785-A1 | ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY | ADORA2A, ADORA2B, ADORA1 | NR1H2 1969/4885NR1H3 2388/4885MLYCD 4804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.